CVR: 13456402
Secondary names: Stamholmen A/S
SYNTESE A/S demonstrates a stable financial health with a slight decline in profitability, reporting a profit of 6.9 million DKK in 2024, down from 7.8 million DKK in 2023. Revenue has shown a consistent upward trend, increasing from 239.8 million DKK in 2022 to 315.1 million DKK in 2024. However, equity has decreased significantly from 166.2 million DKK in 2022 to 75.9 million DKK in 2024, raising concerns about the company's long-term financial stability. The company's position within the organic basic chemicals manufacturing industry appears solid, but the declining profit margins and equity levels warrant close monitoring.
AI-generated summary
Selskabets formål er at drive virksomhed med handel og industri, herunder tilvirkning og salg af lægemidler og kemisk tekniske produkter samt anden i forbindelse hermed stående virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 315.1 mio. | 6.9 mio. | 359.8 mio. | 75.9 mio. | 99 | |
Compared to 14 companies in Fremstilling af andre organiske basiskemikalier
Comparison is based on industry median values
2 properties
Upgrade to Pro to see addresses, building data and ownership details
Nicolas Esmail joined the board
Jens-Eric Regelin left the board
companydata.dk